Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut 1 stage IV NSCLC: phase 1b safety results

被引：0
|
作者：
Nakagawa, K. [1 ]
Garon, E. B. [2 ]
Paz-Ares, L. [3 ]
Ponce, S. [3 ]
Corral Jaime, J. [4 ]
Juan Vidal, O. [5 ]
Nadal, E. [6 ]
Kiura, K. [7 ]
He, S. [8 ]
Treat, J. [8 ]
Dalal, R. [9 ]
Lee, P. [9 ]
Reck, M. [10 ]
Novello, S. [11 ]
机构：
[1] Kinki Univ, Sch Med, Osaka, Japan
[2] UCLA Med Ctr, Santa Monica, CA USA
[3] Hosp Doce Octubre, Madrid, Spain
[4] Hosp Virgen del Rocio, Seville, Spain
[5] Hosp Univ La Fe, Valencia, Spain
[6] Inst Catala Oncol, Barcelona, Spain
[7] Okayama Univ Hosp, Kita Ku, Okayama, Japan
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Eli Lilly & Co, Bridgewater, MA USA
[10] German Ctr Lung Res DZL, ARCN, Lungen Clin Grosshansdorf, Grosshansdorf, Germany
[11] Eli Lilly Italia SpA, Sesto Fiorentino, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E6
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized Phase 1 b/3 Study of Erlotinib plus Ramucirumab in First -Line EGFR Mut plus Stage IV NSCLC: Phase 1 b Safety Results
    Nakagawa, Kazuhiko
    Paz-Ares, Luis
    Ponce, Santiago
    Corral, Jesus
    Vidal, Oscar
    Nadal, Ernest
    Kiura, Katsuyuki
    Liu, Jingyi
    He, Shuang
    Treat, Joseph
    Dalal, Rita
    Lee, Pablo
    Reck, Martin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S285 - S285
  • [2] Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes
    Nakagawa, K.
    Garon, E.
    Paz-Ares, L.
    Ponce, S.
    Corral Jaime, J.
    Juan Vidal, O.
    Nadal, E.
    Kiura, K.
    Park, K.
    Widau, R.
    Alexandris, E.
    He, S.
    Lee, P.
    Reck, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2228 - S2229
  • [3] Erlotinib plus ramucirumab (RAM) as first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation: phase 1B safety results and Phase 3 design of the ongoing Phase 1B/3 study RELAY
    Bischoff, H.
    Garon, E. B.
    Lee, P.
    He, S.
    Kropf-Sanchen, C.
    Kimmich, M.
    Nakagawa, K.
    Reck, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 171 - 171
  • [4] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    Chu, Tianqing
    Zhong, Runbo
    Zhong, Hua
    Zhang, Bo
    Zhang, Wei
    Shi, Chunlei
    Qian, Jialin
    Zhang, Yanwei
    Chang, Qing
    Zhang, Xueyan
    Dong, Yu
    Teng, Jiajun
    Gao, Zhiqiang
    Qiang, Huiping
    Nie, Wei
    Zhao, Yiming
    Han, Yuchen
    Chen, Ya
    Han, Baohui
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 643 - 652
  • [5] Phase 1b study of first-line Ramucirumab plus Platinum plus Fluoropyrimidine in Japanese Patients with advanced gastric cancer
    Kadowaki, Shigenori
    Shitara, Kohei
    Sakai, Daisuke
    Nishina, Tomohiro
    Yoshikawa, Reigetsu
    Piao, Yongzhe
    Ozeki, Akichika
    Inoue, Koichi
    Muro, Kei
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [6] Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin plus /- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
    Sahai, Vaibhav
    Griffith, Kent A.
    Zhen, David Bing
    Deming, Dustin A.
    Shroff, Rachna T.
    Hsieh, David
    Mahalingam, Devalingam
    Crysler, Oxana V.
    Alistar, Angela Tatiana
    Bajor, David L.
    Enzler, Thomas
    Zalupski, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Abemaciclib in Combination with Single Agent Options in Stage IV NSCLC, a Phase 1b Study
    Kelly, Karen
    Goldman, Jonathan W.
    Garrido, Pilar
    Jalal, Shadia
    Mahadevan, Daruka
    Gutierrez, Martin
    Paz-Ares, Luis
    Provencio, Mariano
    Schaefer, Eric
    Shaheen, Monte
    Johnston, Erica L.
    Cai, Na
    John, William J.
    Kim, Edward S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S550 - S550
  • [8] Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
    Sahai, Vaibhav
    Zhen, David Bing
    Crysler, Oxana V.
    Beg, Shaalan Shaalan
    Enzler, Thomas
    Griffith, Kent A.
    Zalupski, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in Patients with ALK plus NSCLC
    Shaw, Alice
    Loong, Herbert
    Tan, Daniel S. -W.
    Griscti, Kerry
    Gao, Haitao
    Finckenstein, Friedrich
    Scott, Jeffrey
    Vansteenkiste, Johan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S430 - S430
  • [10] Preliminary Results of a Phase 1b Study of Bavituximab (B) Plus Carboplatin (C) and Pemetrexed (P) in Chemotherapy-Naive Stage IIIb/IV Nonsquamous NSCLC
    Grilley-Olson, J. E.
    Villaruz, L. C.
    Stinchcombe, T. E.
    Weiss, J.
    Lee, C.
    Shan, J.
    Ivanova, A.
    Moore, D. T.
    Socinski, M. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S54 - S54
12345